JNNP: How does eeritinib treat migraine patients?

Migraine is a highly disabling disease characterized by repeated attacks of severe headaches
.
The trigeminal neurovascular system and the release of calcitonin gene-related peptide (CGRP), a neuromodulator and potent vasodilator, have a crucial role in the pathophysiology of migraine

.

Application of capsaicin on the forehead activates the transient receptor potential cation channel of the trigeminal nerve to release CGRP, thereby increasing forehead skin blood flow (DBF).

Migraine patients were recruited from the Leiden Headache Center
.
The patient did not use any other migraine preventives, nor did he have medication-overuse headaches

.

AUC0-40 (area under the curve from 0 min to 40 min) for DBF response to capsaicin 6.
0 mg/mL in participants with T0 and T1 responses to erenumab <50% and ≥50%

.

A container was placed on the forehead and after 15 min of supine rest, it was filled with capsaicin solution (6.
0 mg/mL in a mixture of 100% ethanol, Tween 20, and distilled water; 3:3:4)
.
DBF was measured continuously for 40 min using a laser Doppler imager (PeriScan PIM (Perfusion Imager) system)

.

A total of 49 patients were invited to participate in the study and all agreed to participate
.
One participant was unable to attend a second study visit due to a debilitating migraine attack and was excluded from all analyses

.

Twelve of these patients had episodic migraine, nine had migraine without aura, and 10 met criteria for allodynia

Capsaicin-induced DBF was used on the forehead to assess CGRP-mediated trigeminal vascular activation before and after eeritinib treatment
.
Regardless of clinical effect, eeritinib (partially) inhibited capsaicin-induced trigeminal vascular activity in all patients

.

However, it is not known whether people who are non-responders to erituzumab are likely to respond to one of the CGRP-binding antibodies
.
Alternatively, CGRP may induce part of its action through a different receptor, such as the amylin type 1 receptor
.
However, it is not known whether people who are non-responders to erituzumab are likely to respond to one of the CGRP-binding antibodies
.
Alternatively, CGRP may induce part of its action through a different receptor, such as the amylin type 1 receptor
.
de Vries Lentsch  S ,  Al-Hassany  L ,  Ferrari  MD de Vries Lentsch  S de Vries Lentsch Al-Hassany  L Al-Hassany Ferrari  MD Ferrari , et al Journal of Neurology, Neurosurgery & Psychiatry  Published Online First:  27 January 2022.
  Published Online First : doi:  10.
1136/jnnp-2021-327992 doi:leave a message here